News

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy.

The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make

The collaboration follows a successful pilot phase, where XtalPi’s integrated quantum physics and AI algorithms achieved improved hit rates, highlighting the platform’s capability to address the complex metabolic target.

EMA has now begun reviewing its use in adults following a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). The validation confirms the application is complete

Upon completion of the transaction, Ignite will separate from Aditxt and is expected to become an independent public company via the establishment of a new holding entity, anticipated

The programme will investigate the ways in which AI can enhance the evaluation of precision and safety, better forecast risks, and identify impacts that current methods might overlook.

The deal centres on enhancing targeted treatments for solid tumours driven by KRAS mutations, which are considered especially challenging to treat. The companies stated that the Firelink DAC

The approval covers patients aged 12 years and older with inhibitors, as well as children aged six to 11 years, with or without inhibitors. Hympavzi is approved for

The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery and development. Since 2021, Sanofi and Owkin have maintained a